首页> 外文期刊>Mini-reviews in organic chemistry >Recent advances in the development of small-molecule compounds targeting HIV- 1 gp41 as membrane fusion inhibitors
【24h】

Recent advances in the development of small-molecule compounds targeting HIV- 1 gp41 as membrane fusion inhibitors

机译:靶向HIV-1 gp41的小分子化合物作为膜融合抑制剂的研究进展

获取原文
获取原文并翻译 | 示例
           

摘要

Over the past few years, remarkable progress has been made in the development of human immunodeficiency virus (HIV) membrane fusion inhibitors. The focus has been on peptide inhibitors, which were developed by mimicking HIV sequences; however, these types of inhibitors generally lack oral bioavailability and are expensive. Therefore, development of small-molecule inhibitors has gained importance and recently progressed. This paper reviews the rapid advancements in the development of small-molecule HIV inhibitors over the last decade.
机译:在过去的几年中,人类免疫缺陷病毒(HIV)膜融合抑制剂的开发取得了显着进展。重点是通过模拟HIV序列开发的肽抑制剂。然而,这些类型的抑制剂通常缺乏口服生物利用度并且价格昂贵。因此,小分子抑制剂的开发变得重要并且最近取得了进展。本文回顾了近十年来小分子HIV抑制剂开发的快速进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号